Kiniksa Pharmaceuticals International (KNSA) Goldman Sachs 45th Annual Global Healthcare Conference summary

Commercial performance and market strategy

• ARCALYST has achieved steady growth since launch, with Q1 revenues of $78.9 million and updated 2024 guidance of $370–390 million.

• Market penetration stands at 9% of a 14,000-patient target, indicating significant growth potential.

• Over 2,000 unique prescribers, with 24% being repeat prescribers responsible for 40% of new Q1 prescriptions.

• Expansion of the field team to 85 representatives and targeted outreach to 11,000 healthcare professionals.

• Focus on education, digital marketing, and patient support programs to drive awareness and adoption.

Patient behavior, treatment duration, and compliance

• Average treatment duration has increased from 6–9 months at launch to about 23 months, reflecting a shift toward maintenance therapy.

• Compliance rates exceed 85%, supported by patient service programs and ongoing education.

• 80% of patients start ARCALYST during an active flare, while 20% begin treatment outside of a flare.

• Most prescribing occurs in cardiology and rheumatology settings, with efforts to improve timely diagnosis.

• Patient drop-off is mainly due to life events, insurance changes, or other health issues, not lack of efficacy.

Market expansion and long-term opportunity

• The company is beginning to target patients with a first recurrence, expanding beyond the initial 14,000-patient core.

• Total addressable market in recurrent pericarditis is considered large, with only 9% penetration so far.

• Business is cash flow positive, enabling reinvestment in commercial and clinical development.

• Financial discipline and capital allocation are emphasized to support sustainable growth.